Report Overview:
This report aims to provide a comprehensive presentation of the global market for Guillain-Barre Syndrome Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Guillain-Barre Syndrome Drugs. This report contains market size and forecasts of Guillain-Barre Syndrome Drugs in global, including the following market information:
Global Guillain-Barre Syndrome Drugs Market Revenue, 2018-2023, 2024-2032, ($ millions)
Global Guillain-Barre Syndrome Drugs Market Sales, 2018-2023, 2024-2032, (K Pcs)
Global top five Guillain-Barre Syndrome Drugs companies in 2023 (%)
Market Value:
Global market size projected to grow from US$ 485 million in 2024 to US$ 692 million in 2030, with a CAGR of 6.1%, and the U.S. market expected to grow from US$ 168 million in 2024 to US$ 235 million in 2030, with a CAGR of 5.8%.
CAGR of 5.8% (2025 – 2032)
By Types:
• Intravenous Immunoglobulin (IVIG)
• Plasma Exchange (Plasmapheresis)
• Corticosteroids
• Monoclonal Antibodies
• Pain Management Drugs
By Applications: Clinic
Hospital
Key players include:
• Akari Therapeutics Plc
• Annexon Inc
• CuraVac Inc
• Hansa Medical AB
• Regenesance BV
• Vitality Biopharma Inc
• Including or Excluding key companies relevant to your analysis.
